Co-principal investigator, Dr Jennifer Connelly, MD, joined Proactive London to update Chris Rhodes on both clinical advancements and the importance of the support received from IQ-AI.
IQ-AI is helping to fund the phase 1 clinical trial at the Medical College of Wisconsin into oral gallium maltolate as a treatment for some types of brain cancer.
The Phase I dose-escalation study is designed to determine the optimal dose of GaM that can be administered safely.